BioSpace News Archive

Lannett Company, Inc. (LCI) (“Lannett” or “the Company”) today announced that it received a written notice from the New York Stock Exchange (“NYSE”) dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company’s common stock from the NYSE.

Tiziana Life Sciences Ltd. today announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer’s Disease in Q2 2023.

ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Pseudomonas aeruginosa (P. aeruginosa).

BioVie Inc. today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry Annual Meeting.

PLT Health Solutions, Inc. announced that it has partnered with Nano Pharmaceuticals Labs, LLC ( Denver, CO ) to market its portfolio of targeted release ingredients on a global basis.

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) announced that CT041, an autologous CAR T-cell product candidate against the protein Claudin18.2 (CLDN18.2), has achieved IND clearance from the National Medical Products Administration (NMPA) for the postoperative adjuvant therapy of CLDN18.2 positive pancreatic cancer (PC).

Abbott announced that it is partnering with the Climate Amplified Disease and Epidemics consortium, a group of more than 100 global scientists in public health agencies, academia and industry focused on using data science technology and diagnostic testing to assess and potentially mitigate the impact climate change has on disease outbreaks.

Heron Therapeutics, Inc. announced changes to its commercial leadership team, including the appointment of Jason Grillot as Vice President, Sales and Marketing, Acute Care, effective April 24, 2023.

Centinel Spine®, LLC, (“the Company”) today announced the completion of the 1,000th procedure in the United States with the Company’s latest FDA-approved total disc replacement (TDR) system of prodisc® cervical solutions, prodisc C Vivo and prodisc C SK.